Microbix Announces Annual Meeting Voting Results

 

MISSISSAUGA, March 26, 2026 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF) (“Microbix®” or the Company”), a life sciences innovator, manufacturer, and exporter, announces the voting results from the Annual Meeting of Shareholders of the Company (the “Meeting”) which was held on March 25, 2026.

 

At the Meeting, 27.44% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the Management Information Circular (the “Circular”) dated February 6, 2026. The Circular is available on the Company’s website (https://www.microbix.com) and on SEDAR+ (https://www.sedarplus.ca).

 

All of the board of directors nominees listed in the Circular were re-elected as directors of Microbix. Results of the vote were as follows:

 

 

Nominee	Votes For	% Votes For	Withheld	% Withheld
Peter M. Blecher	36,372,515	99.77%	83,900	0.23%
Mark A. Cochran	36,370,515	99.76%	85,900	0.24%
Vaughn C. Embro-Pantalony	35,731,938	98.01%	724,477	1.99%
Joseph D. Renner	36,370,515	99.76%	85,900	0.24%
Martin Marino	36,370,515	99.76%	85,900	0.24%
Cameron Groome	35,793,938	98.18%	662,477	1.82%
Jennifer Stewart	31,377,765	86.07%	5,078,650	13.93%

 

Shareholders also approved a resolution re-appointing the Company’s auditors, Ernst & Young LLP, with 96.66% of the votes cast in favour.

 

The slides of management’s presentation at the Meeting have been posted at https://www.microbix.com.

 

About Microbix Biosystems Inc.

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.5 million in its latest fiscal year (2025). It makes a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) and reference materials (QUANTDx™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

 

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or medial to support diagnostic testing (e.g., its DxTM™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

 

Forward-Looking Information

 

This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, discussion of Microbix’s business and business results, goals or outlook, risks associated with financial results and stability, development projects such as those referenced in its corporate presentation, regulatory compliance and approvals, sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information except as required by applicable law.

.

Please visit www.microbix.com or https://www.sedarplus.ca for recent Microbix news and filings.

 

For further information, please contact Microbix at:

Cameron Groome, CEO (905) 361-8910

Jim Currie, CFO (905) 361-8910

Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com

Copyright © 2026 Microbix Biosystems Inc.

Microbix®, DxTM™, Kinlytic®, QAPs™, and QUANTDx™ are trademarks of Microbix Biosystems Inc.

Other companies’ names and products are protected by their respective trademarks.